Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-06-01-Speech-4-150"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2006-06-01"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20060601.27.4-150"2
lpv:hasSubsequent	lp_eu:2006-06-01-Speech-4-1512
lpv:speaker	lp:Vittorio Agnoletto2
lpv:spokenAs	member; EUL/NGL (2004-07-20--2009-07-13)3 member; DROI (2004-07-21--2007-01-14)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2004-09-15--2009-07-13)3 substitute; Delegation for relations with the United States (2004-09-15--2007-03-13)3 substitute; INTA (2004-07-21--2007-01-14)3 member; AFET (2004-07-21--2007-01-14)3 unknown; Partito della Rifondazione Comunista - Sinistra Europea (2004-07-20--2009-07-13)3
lpv:translated text	"Mr President, regarding the vote on the issue of paediatric medicines, I should just like to point out that, after the six-month patent extension granted to the multinational drug companies at first reading, I feel that extending the transition period during which that additional protection certificate can be applied for from two years to five years is really going too far. That is why I voted against Amendment 18, and also because the benefits to the paediatric population cannot be scientifically documented. In addition, accepting that amendment might encourage research into paediatric indications for medicines produced for adult use, precisely going against one of the aims of the regulation."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph